Kelly Jason R
See remarks
Kelly Jason R has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Apr 10, 2026.
On the most recent filing, Kelly Jason R is listed as See remarks at Ginkgo Bioworks Holdings, Inc. Inside the rolling window, Kelly Jason R reported no open-market purchases and 2 open-market sales totaling $1.4M in DNA. The largest disclosed transaction in the window is a sale of 109,767 DNA shares on Apr 9, 2026, worth $702K.
Companies traded
Other insiders at DNA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kelly Jason R made?
Kelly Jason R has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does Kelly Jason R trade?
Kelly Jason R has filed SEC Form 4 disclosures for 1 company, including DNA.
When was Kelly Jason R's most recent SEC Form 4 filing?
Kelly Jason R's most recent SEC Form 4 filing on Tracefour is dated Apr 10, 2026.
What is Kelly Jason R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kelly Jason R is listed as See remarks.
What is Kelly Jason R's total buy and sell value in the current window?
Inside the rolling retention window, Kelly Jason R bought $0 and sold $1.4M based on SEC Form 4 filings.
What was Kelly Jason R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 109,767 DNA shares on 2026-04-09, worth $702K, per SEC Form 4 filings.